Ivan Gergel - Nektar Therapeutics President
NKTR Stock | USD 0.93 0.04 4.49% |
President
Dr. Ivan P. Gergel, M.D., is Senior Vice President Drug Development Chief Medical Officer of the Company. Dr. Gergel served as Executive Vice President, Research Development and Chief Scientific Officer of Endo Pharmaceuticals, a pharmaceutical company. Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr. Gergel is a member of the Board of Directors of Corium International, Inc., a commercialstage biopharmaceutical company since 2014.
Age | 56 |
Tenure | 10 years |
Professional Marks | MBA |
Address | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
Phone | 415 482 5300 |
Web | https://www.nektar.com |
Nektar Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1095) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/29/2024, Return On Capital Employed is likely to grow to -0.38. In addition to that, Return On Assets is likely to grow to -0.66. At this time, Nektar Therapeutics' Total Assets are relatively stable compared to the past year. As of 03/29/2024, Non Currrent Assets Other is likely to grow to about 8.3 M, while Other Assets are likely to drop slightly above 2.5 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
Monique Matheson | Nike Inc | 57 | |
Kevin Page | Wabash National | 62 | |
Mark Barrett | American Axle Manufacturing | 55 | |
Revital Avrahami | Shagrir Group Vehicle | 47 | |
Mike Pettit | Wabash National | N/A | |
Chris Abston | Nike Inc | 54 | |
Allan Brazier | Aptiv PLC | 57 | |
Gregory Deveson | American Axle Manufacturing | 58 | |
David Ayre | Nike Inc | 56 | |
Mariya Trickett | Aptiv PLC | 38 | |
Neil Boehm | Gentex | 52 | |
Mark Weber | Wabash National | 44 | |
Steve Downing | Gentex | 37 | |
Donald Joseph | American Axle Manufacturing | 60 | |
Susan Suver | Aptiv PLC | 57 | |
Matthew Friend | Nike Inc | 45 | |
Jeanne Jackson | Nike Inc | 64 | |
Jerome Dorlack | Aptiv PLC | 36 | |
Angelo Labbadia | Eastern Co | 66 | |
Haim Leibovich | Shagrir Group Vehicle | 46 | |
Itzhak Gol | Shagrir Group Vehicle | 41 |
Management Performance
Return On Equity | -1.11 | ||||
Return On Asset | -0.15 |
Nektar Therapeutics Leadership Team
Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer | ||
Mark Wilson, Chief Sec | ||
Lutz Lingnau, Independent Director | ||
Roy Whitfield, Independent Director | ||
Scott Greer, Independent Director | ||
Mary Tagliaferri, Senior Vice President - Clinical Development and Chief Medical Officer | ||
Christopher Kuebler, Independent Director | ||
Karin Eastham, Independent Director | ||
Jeff Ajer, Independent Director | ||
Maninder Hora, Senior Vice President - Pharmaceutical Development and Manufacturing Operations | ||
Brian MD, Chief Officer | ||
Robert Chess, Independent Chairman of the Board | ||
Wei Lin, Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs | ||
Dennis Winger, Independent Director | ||
Vivian Wu, Director Affairs | ||
Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs | ||
Sandra Gardiner, Interim Officer | ||
Kevin Brodbeck, VP Operations | ||
Joseph Krivulka, Independent Director | ||
Gilbert Labrucherie, Senior Vice President General Counsel, Secretary | ||
John Nicholson, CFO and Sr. VP | ||
Stephen Doberstein, Chief Scientific Officer and Sr. VP | ||
Howard Robin, CEO and President and Director | ||
Ivan Gergel, Senior Vice President - Drug Development & Chief Medical Officer | ||
MD LAc, Chief Officer | ||
John Northcott, Strategic Advisor | ||
Loui Madakamutil, VP Research | ||
Robert Bacci, Senior Operations | ||
Susan Wang, Independent Director | ||
Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin. |
Nektar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.11 | ||||
Return On Asset | -0.15 | ||||
Operating Margin | (1.28) % | ||||
Current Valuation | (13.24 M) | ||||
Shares Outstanding | 183.62 M | ||||
Shares Owned By Insiders | 1.01 % | ||||
Shares Owned By Institutions | 67.39 % | ||||
Number Of Shares Shorted | 2.51 M | ||||
Price To Earning | 8.02 X | ||||
Price To Book | 1.32 X |
Nektar Therapeutics Investors Sentiment
The influence of Nektar Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Nektar. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Nektar Therapeutics' public news can be used to forecast risks associated with an investment in Nektar. The trend in average sentiment can be used to explain how an investor holding Nektar can time the market purely based on public headlines and social activities around Nektar Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Nektar Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Nektar Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Nektar Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Nektar Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nektar Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nektar Therapeutics' short interest history, or implied volatility extrapolated from Nektar Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Nektar Stock analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.474 | Quarterly Revenue Growth 0.085 | Return On Assets (0.15) | Return On Equity (1.11) |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.